利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.025 秒)

    Isolated protein comprising an activin type IIB5 receptor polypeptide and uses thereof
    3.
    发明授权
    Isolated protein comprising an activin type IIB5 receptor polypeptide and uses thereof 有权
    包含激活素IIB5型受体多肽的分离蛋白及其用途

    公开(公告)号：US08614292B2

    公开(公告)日：2013-12-24

    申请号：US13190255

    申请日：2011-07-25

    申请人： HQ Han ,  Keith Soo-Nyung Kwak ,  Xiaolan Zhou

    发明人： HQ Han ,  Keith Soo-Nyung Kwak ,  Xiaolan Zhou

    IPC分类号： A61K38/00 ,  A61K38/18 ,  A61P3/04 ,  C07K14/51

    CPC分类号： C07K14/71 ,  C07K2319/30

    摘要： The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.

    摘要翻译： 本发明提供能够结合并抑制活化素A，肌生成抑制素或GDF-11的活性的新型激活素IIB5受体多肽。 本发明还提供能够产生受体多肽的多核苷酸，载体和宿主细胞。 还提供了用于治疗肌肉消瘦，代谢和其它疾病的组合物和方法。

    Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
    4.
    发明授权
    Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 有权
    分离的核酸分子，其包含SEQ ID NO：1的氨基酸序列

    公开(公告)号：US08067562B2

    公开(公告)日：2011-11-29

    申请号：US11590962

    申请日：2006-10-31

    申请人： HQ Han ,  Keith Soo-Nyung Kwak ,  Xiaolan Zhou

    发明人： HQ Han ,  Keith Soo-Nyung Kwak ,  Xiaolan Zhou

    IPC分类号： C07H21/04 ,  C12P21/06 ,  C12N15/00 ,  C12N5/02

    CPC分类号： C07K14/71 ,  C07K2319/30

    摘要： The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.

    摘要翻译： 本发明提供能够结合并抑制活化素A，肌生成抑制素或GDF-11的活性的新型激活素IIB5受体多肽。 本发明还提供能够产生受体多肽的多核苷酸，载体和宿主细胞。 还提供了用于治疗肌肉消瘦，代谢和其它疾病的组合物和方法。

    BIFUNCTIONAL ANTAGONISTS OF ACTIVIN/TGF-BETA AND RANKL AND USES THEREOF
    5.
    发明公开
    BIFUNCTIONAL ANTAGONISTS OF ACTIVIN/TGF-BETA AND RANKL AND USES THEREOF 审中-公开

    公开(公告)号：US20230391880A1

    公开(公告)日：2023-12-07

    申请号：US18034708

    申请日：2021-11-05

    申请人： HQ Han ,  Xiaolan Zhou

    发明人： HQ Han ,  Xiaolan Zhou

    IPC分类号： C07K16/28 ,  C07K16/22 ,  C07K14/71

    CPC分类号： C07K16/2875 ,  C07K16/22 ,  C07K14/71 ,  A61K2039/505

    摘要： This invention disclosure provides novel bifunctional molecules comprising at least one RANKL binding molecule and at least one Activin or TGF-β binding molecule, which are capable of sequestering RANKL and Activin or TGF-β in parallel. Also provided are pharmaceutical compositions of such bifunctional antagonist molecules and their therapeutic uses to treat various bone disorders whose pathogenesis involves the activation of both RANKL-NFκB and Activin/TGFβ-Smad2/3 signaling pathways, such as bone metastasis, bone loss in cancer, bone fragility in neuromuscular diseases, osteogenesis imperfecta, fracture, osteopenia and osteoporosis.

    NOVEL BIFUNCTIONAL MULTISPECIFIC ANTAGONISTS CAPABLE OF INHIBITING MULTIPLE LIGANDS OF TGF-BETA FAMILY AND USES THEREOF
    6.
    发明公开
    NOVEL BIFUNCTIONAL MULTISPECIFIC ANTAGONISTS CAPABLE OF INHIBITING MULTIPLE LIGANDS OF TGF-BETA FAMILY AND USES THEREOF 审中-公开

    公开(公告)号：US20240343788A1

    公开(公告)日：2024-10-17

    申请号：US18034499

    申请日：2021-10-29

    申请人： HQ Han ,  Xiaolan Zhou

    发明人： HQ Han ,  Xiaolan Zhou

    IPC分类号： C07K16/22 ,  A61K39/00 ,  C07K16/28

    CPC分类号： C07K16/22 ,  C07K16/2818 ,  C07K16/2827 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/76

    摘要： This invention disclosure describes novel polypeptide antagonists capable of neutralizing multiple members of TGF-β family in a selective manner. Specifically, the multispecific polypeptide antagonists disclosed herein comprise at least one Activin-binding domain and at least one TGF-β-binding domain and therefore, are capable of neutralizing TGF-β and Activin as well as Activin-related ligands in parallel. Moreover, this invention disclosure also discloses bifunctional multispecific polypeptide antagonists designed to inhibit Activin, TGF-β and T-Cell immune checkpoint (i.e., PD1, PDL1 or CTLA4) in a simultaneous manner. Specifically, the bifunctional multispecific antagonists disclosed herein comprise at least one Activin-binding domain, at least one TGF-β-binding domain and at least one PD1-, PDL1- or CTLA4-binding domain. Also provided are pharmaceutical compositions of such multispecific or bifunctional multispecific polypeptide antagonists and their therapeutic uses for treating certain disease conditions, which involve overexpression of both TGF-β and Activin, such as fibrosis and cancer.